# Isodon lophanthoides alleviates liver fibrosis via modulation of purine metabolism and NF-κB signaling pathway: insights from multi-omics analysis

**Authors:** Kuikui Chen, Jie Liang, Yong Tan, Yaohua Li, Xiaojiao Pan, Zhonghui Guo, Wentao Zhang, Zongxi Sun

PMC · DOI: 10.3389/fphar.2025.1630927 · 2025-08-01

## TL;DR

Isodon lophanthoides reduces liver fibrosis by modulating purine metabolism and inhibiting the NF-κB pathway, as shown in a mouse model and multi-omics analysis.

## Contribution

The study reveals the anti-fibrotic mechanisms of Isodon lophanthoides through integrated multi-omics analysis and experimental validation.

## Key findings

- ILW treatment reduced liver fibrosis markers and inflammation in mice.
- ILW modulates purine metabolism and inhibits NF-κB signaling pathway.
- High-dose ILW alters hepatic metabolite levels and downregulates pro-inflammatory proteins.

## Abstract

Isodon lophanthoides, a core botanical drug in Yao ethnomedicine, has traditionally been used to treat jaundice-type hepatitis and cholecystitis. However, its therapeutic potential and mechanisms against liver fibrosis remain largely unexplored.

The metabolites of I. lophanthoides water extract (ILW) were characterized by ultra-performance liquid chromatography (UPLC) and UPLC coupled with quadrupole time-of-flight mass spectrometry (Q-TOF/MS). A carbon tetrachloride (CCl4)-induced liver fibrosis mouse model was employed to evaluate the anti-fibrotic effects of ILW. An integrated multi-omics approach encompassing transcriptomics, proteomics, and metabolomics was used to elucidate the underlying mechanisms, further supported by Western blotting, targeted metabolite quantification, and enzyme-linked immunosorbent assay (ELISA).

Thirty-two metabolites were identified in ILW. Among them, the concentrations of caffeic acid, rosmarinic acid, schaftoside, and isoschaftoside were determined to be 1.10, 5.13, 0.12, and 0.18 mg·g-1, respectively. ILW treatment significantly reduced serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), procollagen type III (PC-III), collagen type IV (COL-IV), laminin (LN), and hyaluronic acid (HA) in liver fibrotic mice. Histopathological analyses showed that ILW significantly alleviated liver inflammation, collagen deposition, and fibrosis. Multi-omics analysis revealed that ILW’s anti-fibrotic effects are linked to modulation of purine metabolism and inhibition of the nuclear factor kappa-B (NF-κB) signaling pathway. High-dose ILW lowered hepatic levels of adenine, adenosine monophosphate (AMP), and inosine monophosphate (IMP), while increasing adenosine, hypoxanthine, and N6-methyladenosine (m6A). Furthermore, high-dose and medium-dose ILW downregulated key NF-κB-related proteins, including toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), phosphorylated NF-κB, transforming growth factor beta 1 (TGF-β1), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β).

ILW exerts protective effects against liver fibrosis by attenuating inflammation, fibrosis, and liver damage through modulation metabolism modulation and NF-κB pathway inhibition. These findings provide a scientific basis for the traditional use of I. lophanthoides in liver-related disorders.

## Linked entities

- **Proteins:** TLR4 (toll like receptor 4), MYD88 (MYD88 innate immune signal transduction adaptor), NFKB1 (nuclear factor kappa B subunit 1), TGFB1 (transforming growth factor beta 1), TNF (tumor necrosis factor), IL6 (interleukin 6), IL1B (interleukin 1 beta)
- **Chemicals:** CCl4 (PubChem CID 5943), ALT (PubChem CID 10219674), LN (PubChem CID 4128305), HA (PubChem CID 854026), adenine (PubChem CID 190), AMP (PubChem CID 6083), IMP (PubChem CID 135398640), adenosine (PubChem CID 60961), hypoxanthine (PubChem CID 135398638), m6A (PubChem CID 102175)
- **Diseases:** cholecystitis (MONDO:0002155)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Slc17a5 (solute carrier family 17 (anion/sugar transporter), member 5) [NCBI Gene 235504] {aka 4631416G20Rik, 4732491M05, AST, ISSD, NSD, SD}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Myd88 (myeloid differentiation primary response gene 88) [NCBI Gene 17874], Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Gpt (glutamic pyruvic transaminase, soluble) [NCBI Gene 76282] {aka 1300007J06Rik, 2310022B03Rik, ALT, ALT1, Gpt-1, Gpt1}
- **Diseases:** inflammation (MESH:D007249), hepatitis (MESH:D056486), liver (MESH:D017093), fibrosis (MESH:D005355), cholecystitis (MESH:D002764), liver fibrosis (MESH:D008103), jaundice (MESH:D007565)
- **Chemicals:** HA (MESH:D006820), IMP (MESH:D007291), CCl4 (MESH:D002251), N6-methyladenosine (MESH:C010223), rosmarinic acid (MESH:C041376), adenine (MESH:D000225), AMP (MESH:D000249), hypoxanthine (MESH:D019271), caffeic acid (MESH:C040048), isoschaftoside (MESH:C515113), adenosine (MESH:D000241), m6A (MESH:C005955), schaftoside (MESH:C515112)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Isodon lophanthoides (species) [taxon 204133]

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12354614/full.md

---
Source: https://tomesphere.com/paper/PMC12354614